- Home
- AEHL vs IMRN Comparison
AEHL vs IMRN Comparison
Compare AEHL & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEHL
- IMRN
- Stock Information
- Founded
- AEHL 1993
- IMRN 1994
- Country
- AEHL China
- IMRN Australia
- Employees
- AEHL N/A
- IMRN N/A
- Industry
- AEHL Building Materials
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AEHL Industrials
- IMRN Health Care
- Exchange
- AEHL Nasdaq
- IMRN Nasdaq
- Market Cap
- AEHL 8.5M
- IMRN 9.2M
- IPO Year
- AEHL 2007
- IMRN N/A
- Fundamental
- Price
- AEHL $2.75
- IMRN $1.74
- Analyst Decision
- AEHL
- IMRN Strong Buy
- Analyst Count
- AEHL 0
- IMRN 1
- Target Price
- AEHL N/A
- IMRN $5.00
- AVG Volume (30 Days)
- AEHL 123.4K
- IMRN 24.7K
- Earning Date
- AEHL 05-01-2025
- IMRN 07-07-2025
- Dividend Yield
- AEHL N/A
- IMRN N/A
- EPS Growth
- AEHL N/A
- IMRN N/A
- EPS
- AEHL N/A
- IMRN N/A
- Revenue
- AEHL $98,773,000.00
- IMRN $4,048,286.00
- Revenue This Year
- AEHL N/A
- IMRN N/A
- Revenue Next Year
- AEHL N/A
- IMRN N/A
- P/E Ratio
- AEHL N/A
- IMRN N/A
- Revenue Growth
- AEHL 36.99
- IMRN 82.90
- 52 Week Low
- AEHL $1.79
- IMRN $1.50
- 52 Week High
- AEHL $256.40
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- AEHL 53.14
- IMRN 58.70
- Support Level
- AEHL $2.33
- IMRN $1.68
- Resistance Level
- AEHL $2.75
- IMRN $1.94
- Average True Range (ATR)
- AEHL 0.25
- IMRN 0.09
- MACD
- AEHL 0.05
- IMRN 0.02
- Stochastic Oscillator
- AEHL 69.70
- IMRN 76.92
About AEHL Antelope Enterprise Holdings Limited
Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.